Taiwan FDA registration f9ddfede5c3807133486c09a262e0532
"Kaijie" Anminning Membrane Rupture (Placental Microglobulin) Assay (Sterilized)
TW: "凱杰" 安敏寧胎膜破裂(胎盤微球蛋白)檢測劑 (滅菌)
Taiwan·Risk Class 1·QIAGEN·Registered Jul 31, 2017 – Jul 31, 2027ActiveRegistration details
- Analysis ID
- f9ddfede5c3807133486c09a262e0532
- Customs Code
- DHA09401813200
Company information
- Manufacturer
- QIAGEN
- Manufacturer Country
- United States
- Authorized Representative
- QIAGEN TAIWAN COMPANY LIMITED
Product details
- Intended Use
- It is limited to the first level of identification scope of the "Uric pH (Non-quantitative) Test System (A.1550)" of the Measures for the Classification and Grading of Medical Devices.
- Product Type (Level 1)
- A Clinical chemistry and clinical toxicology
- Product Type (Level 2)
- A.1550 Uric pH (non-quantitative) testing system
- Import Information
- QMS/QSD;; 輸入
Dates and status
- Registration Date
- Jul 31, 2017
- Expiry Date
- Jul 31, 2027
About this record
Access comprehensive regulatory information for "Kaijie" Anminning Membrane Rupture (Placental Microglobulin) Assay (Sterilized) in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 1 medical device is registered under number f9ddfede5c3807133486c09a262e0532 and manufactured by QIAGEN. The authorized representative in Taiwan is QIAGEN TAIWAN COMPANY LIMITED.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices